Johnson & Johnson (JNJ)
(Real Time Quote from BATS)
$146.47 USD
+0.73 (0.50%)
Updated Apr 19, 2024 11:06 AM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Company Summary
Johnson & Johnson’s biggest strength is its diversified business model. It operates through pharmaceuticals and medical devices divisions. It has more than 275 subsidiaries, which clearly means that the business is extremely well diversified. Its diversification helps it to withstand economic cycles more effectively. J&J has 26 platforms with more than $1 billion in annual sales. Meanwhile, J&J has one of the largest R&D budgets among pharma companies.
In August 2023, J&J completely separated its Consumer Health business into a newly listed company called Kenvue, which now operates ...
Company Summary
Johnson & Johnson’s biggest strength is its diversified business model. It operates through pharmaceuticals and medical devices divisions. It has more than 275 subsidiaries, which clearly means that the business is extremely well diversified. Its diversification helps it to withstand economic cycles more effectively. J&J has 26 platforms with more than $1 billion in annual sales. Meanwhile, J&J has one of the largest R&D budgets among pharma companies.
In August 2023, J&J completely separated its Consumer Health business into a newly listed company called Kenvue, which now operates as a separate and fully independent company. After completion of the exchange offer, J&J now has a 9.5% stake (approximately 180 million shares) in Kenvue’s common stock, which it may monetize in a tax-efficient manner in 2024. With the complete separation of the Consumer Health segment, J&J has now become a two-sector company focused on the Pharmaceutical and MedTech fields.
New Brunswick, NJ-based J&J’s worldwide business is divided into two segments: Innovative Medicine and MedTech. In 2023, these segments contributed 64.0% and 36.0%, respectively, to the company’s total revenues of $85.2 billion (up 6.5%).
Innovative Medicine Segment (previously referred to as Pharmaceutical) – Johnson & Johnson has one of the most diverse revenue streams in the industry within the pharmaceutical division. The company has several multi-million-dollar drugs covering a broad range of areas such as neuroscience, cardiovascular and metabolism, immunology, oncology, pulmonary hypertension and infectious diseases. Innovative Medicine segment sales in 2023 totaled $54.8 billion, up 4.2%.
MedTech Segment – This segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The segment posted sales of $30.4 billion in 2023, up 10.8%.
General Information
Johnson & Johnson
ONE JOHNSON & JOHNSON PLZ
NEW BRUNSWICK, NJ 08933
Phone: 732-524-0400
Fax: 732-214-0332
Web: http://www.jnj.com
Email: investor-relations@its.jnj.com
Industry | Large Cap Pharmaceuticals |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 3/31/2024 |
Exp Earnings Date | 7/18/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 2.74 |
Current Year EPS Consensus Estimate | 10.65 |
Estimated Long-Term EPS Growth Rate | 5.70 |
Exp Earnings Date | 7/18/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 145.74 |
52 Week High | 175.97 |
52 Week Low | 143.13 |
Beta | 0.53 |
20 Day Moving Average | 7,172,390.50 |
Target Price Consensus | 175.12 |
4 Week | -6.43 |
12 Week | -8.66 |
YTD | -7.02 |
4 Week | -2.12 |
12 Week | -10.79 |
YTD | -11.49 |
Shares Outstanding (millions) | 2,409.78 |
Market Capitalization (millions) | 351,201.78 |
Short Ratio | NA |
Last Split Date | 6/13/2001 |
Dividend Yield | 3.27% |
Annual Dividend | $4.76 |
Payout Ratio | 0.46 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | 2/16/2024 / $1.19 |
Fundamental Ratios
P/E (F1) | 13.69 |
Trailing 12 Months | 13.93 |
PEG Ratio | 2.40 |
vs. Previous Year | 1.12% |
vs. Previous Quarter | 18.34% |
vs. Previous Year | -13.59% |
vs. Previous Quarter | -0.06% |
Price/Book | 5.10 |
Price/Cash Flow | 10.66 |
Price / Sales | 3.92 |
3/31/24 | 36.43 |
12/31/23 | 37.27 |
9/30/23 | 37.14 |
3/31/24 | 15.01 |
12/31/23 | 14.84 |
9/30/23 | 14.80 |
3/31/24 | NA |
12/31/23 | 1.16 |
9/30/23 | 1.21 |
3/31/24 | NA |
12/31/23 | 0.91 |
9/30/23 | 0.96 |
3/31/24 | 29.31 |
12/31/23 | 28.77 |
9/30/23 | 28.76 |
3/31/24 | 45.26 |
12/31/23 | 37.79 |
9/30/23 | 36.32 |
3/31/24 | 24.80 |
12/31/23 | 17.69 |
9/30/23 | 14.40 |
3/31/24 | NA |
12/31/23 | 28.57 |
9/30/23 | 29.59 |
3/31/24 | 2.10 |
12/31/23 | 2.21 |
9/30/23 | 2.22 |
3/31/24 | NA |
12/31/23 | 0.38 |
9/30/23 | 0.37 |
3/31/24 | NA |
12/31/23 | 27.34 |
9/30/23 | 26.78 |